Drugs / BPC-2001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07246031 | Oct 2025 → Nov 2027 expected | acute graft versus host disease, chronic graft versus host disease | BioPhoenix Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BPC-2001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07246031 ↗ |
| Route | Intravenous | “100 μg/kg via IV administration” NCT07246031 ↗ |